Pipeline — registered trials by phase
Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis
— · Psoriasis · Completed · est. 2024-01-11
Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma
— · Melanoma · Completed · est. 2018-03-07
Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers
— · Healthy Volunteers · Recruiting · est. 2026-11-30
A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes
— · Diabetes Mellitus, Non-Insulin-Dependent · Completed · est. 2003-06
Dose Escalation With Remicade® and Orencia®
— · Rheumatoid Arthritis · Completed · est. 2010-08
Safety Study of Abatacept to Treat Rheumatoid Arthritis
— · Rheumatoid Arthritis · Completed · est. 2014-12-31
A Study to Evaluate the Effect of KarXT on Urological Safety
— · Schizophrenia · Recruiting · est. 2027-12-30
Long-term Epidemiological Follow-up of Non-small Cell Lung Cancer in Scandinavia
— · Non-Small Cell Lung Cancer · Completed · est. 2020-01-31
A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea
— · Ulcerative Colitis · Recruiting · est. 2028-04-01
ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE
— · Venous Thromboembolism · Completed · est. 2018-07-31
A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
— · Acute Coronary Syndromes · Completed · est. 2018-11-10
A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan
— · Melanoma · Completed · est. 2018-12-29
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
— · Ulcerative Colitis · Recruiting · est. 2034-06-30
Changes in the Use of Opioids, Antidepressants, and Benzodiazepines in Rheumatoid Arthritis Patients Treated With Biologic Agents
— · Rheumatoid Arthritis · Completed · est. 2010-10
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
— · Follicular Lymphoma · Recruiting · est. 2044-08-31
Rescue Treatment Pattern, Drug Resistance Recurrence, and Direct Medical Costs Associated With Chinese Patients With Chronic Hepatitis B and Drug Resistance to Nucleot(s)Ide Analogue Therapy
— · Hepatitis B · Completed · est. 2017-10-30
Economic Burden in Adult Patients Diagnosed With Rheumatoid Arthritis (RA) Receiving Treatment With Biologic Disease-modifying Antirheumatic Drugs (bDMARDs)
— · Rheumatoid Arthritis · Completed · est. 2011-04
KarXT Concentrations in the Breast Milk and Plasma of Lactating Females
— · Healthy Volunteers · Completed · est. 2026-06-08
Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C
— · Chronic Hepatitis C · Completed · est. 2017-01-20
A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
— · Psoriasis · Completed · est. 2024-08-23
Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)
— · Chronic Myeloid Leukemia · Completed · est. 2012-12
A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
— · Cancer · Completed · est. 2023-02-27
Dasatinib in Combination With Revlimid (and Dexamethasone)
— · Multiple Myeloma · Completed · est. 2011-10
A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.
— · Severe Sepsis · Completed · est. 2018-01-05
Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects
— · Atherosclerosis · Completed · est. 2009-07
A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants
— · Healthy Volunteers · Completed · est. 2025-03-16
Pharmacokinetics and Metabolism Study in Healthy Male Participants
— · Cancer · Completed · est. 2017-10-15
Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects
— · Autoimmune Diseases · Completed · est. 2019-09-25
Safety and Tolerability Study of AVID200 in Pts With Diffuse Cutaneous Systemic Sclerosis
— · Scleroderma, Diffuse · Completed · est. 2020-06-20
A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants
— · Healthy Volunteers · Completed · est. 2023-07-06
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Participants With Atopic Dermatitis
— · Dermatitis, Atopic · Completed · est. 2025-11-06
A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects
— · Healthy Volunteers · Completed · est. 2019-02-19
Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma
— · Hodgkin's Lymphomas · Completed · est. 2010-01
Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
— · Healthy Participants · Completed · est. 2021-03-21
An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment
— · Advanced Cancer · Completed · est. 2021-03-31
A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants
— · Healthy Volunteers · Completed · est. 2023-08-14
A Study Comparing Two Forms of Didanosine in HIV-infected Patients
— · HIV Infections · Completed · est. 1999-03
A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus
— · Lupus Erythematosus, Cutaneous · Completed · est. 2023-04-21
A Study of MDX-1106 to Treat Patients With Hepatitis C Infection
— · Hepatitis C · Completed · est. 2009-10
Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325
— · Hepatitis C · Completed · est. 2014-07
Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor
— · CANCER, NOS · Completed · est. 2015-04
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients
— · Hepatitis C Infection · Completed · est. 2010-09
Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
— · Rheumatoid Arthritis · Completed · est. 2013-02
A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis
— · Crohn Disease, Ulcerative Colitis · Completed · est. 2023-08-29
Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney
— · Graft Rejection, Kidney Transplantation, Renal Transplantation · Completed · est. 2004-01
Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression
— · Depression · Completed · est. 2013-01
Study in Japan of the Safety And Antiviral Activity in Adults With Chronic Hepatitis B Current Lamivudine Therapy
— · Chronic Hepatitis B · Completed · est. 2005-02
A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
— · Non-Alcoholic Steatohepatitis · Completed · est. 2017-01-18
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis
— · Vascular Diseases · Completed · est. 2010-11
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
— · Advanced Solid Tumors · Active Not Recruiting · est. 2026-09-05
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
— · Colorectal Cancer (CRC) · Completed · est. 2011-09
Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer
— · Non-small Cell Lung Cancer · Completed · est. 2005-05
Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers
— · Systemic Lupus Erythematosus, Sjögren's Disease, Psoriasis · Not Yet Recruiting · est. 2030-10-31
Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection
— · Hepatitis B, Chronic · Completed · est. 2011-03
A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.
— · Diabetes Mellitus, Non-Insulin-Dependent · Completed · est. 2003-10
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
— · Irritability Associated With Autism Spectrum Disorder · Not Yet Recruiting · est. 2029-08-06
Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B
— · Hepatitis B, Chronic · Completed · est. 2010-10
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma
— · Melanoma · Completed · est. 2021-11-19
A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
— · Rheumatoid Arthritis · Completed · est. 2009-10
A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1
— · Hepatitis C Virus · Completed · est. 2015-06-12
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
— · Melanoma · Active Not Recruiting · est. 2022-06-28
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
— · Melanoma, Metastases · Completed · est. 2009-08
BaracludeEntecavir
EliquisApixaban
EmplicitiElotuzumab
IdhifaEnasidenib Mesylate
NulojixBelatacept
OpdivoNivolumab
OpdualagNivolumab
OrenciaAbatacept
RevlimidLenalidomide
ReyatazAtazanavir Sulfate
SprycelDasatinib
YervoyIpilimumab
ZenbexusIberdomide Hydrochloride
Source: ClinicalTrials.gov (trials where Bristol Myers Squibb is lead sponsor; 62 active or completed) and Drugs@FDA (13 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- SCHEDULE 13G2026-08-07SCHEDULE 13G
- 10-Q2026-07-30Quarterly report
- 8-K2026-07-30Current report (material event)
- 11-K2026-06-0511-K
- 11-K2026-06-0511-K
- 11-K2026-06-0511-K
- S-82026-05-08Employee stock plan
- 8-K2026-05-08Current report (material event)
- 10-Q2026-04-30Quarterly report
- 8-K2026-04-30Current report (material event)
- SCHEDULE 13G2026-04-29SCHEDULE 13G
- DEFA14A2026-04-17DEFA14A
- 15-12G2026-03-2715-12G
- SCHEDULE 13G/A2026-03-26SCHEDULE 13G/A
- ARS2026-03-25Annual report to holders
- DEFA14A2026-03-25DEFA14A
- DEF 14A2026-03-25Proxy statement
- 10-K2026-02-11Annual report
- 8-K2026-02-05Current report (material event)
- 8-K2026-01-12Current report (material event)
- 8-K2025-11-18Current report (material event)
- CERT2025-11-12CERT
- 8-A12B2025-11-108-A12B
- 8-K2025-11-10Current report (material event)
- 424B52025-11-07Prospectus (offering)
- FWP2025-11-05FWP
- 8-K2025-11-03Current report (material event)
- 424B22025-11-03424B2
- POSASR2025-10-31POSASR
- SCHEDULE 13G/A2025-10-31SCHEDULE 13G/A
- 10-Q2025-10-30Quarterly report
- 8-K2025-10-30Current report (material event)
- 10-Q2025-07-31Quarterly report
- 8-K2025-07-31Current report (material event)
- 8-K2025-07-25Current report (material event)
- 11-K2025-06-0611-K
- 11-K2025-06-0611-K
- 11-K2025-06-0611-K
- 25-NSE2025-05-1525-NSE
- SC TO-T/A2025-05-13SC TO-T/A
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.